What Funed - Fundação Ezequiel Dias does

Fundação Ezequiel Dias (Funed) is a public foundation established in 1900 and headquartered in Belo Horizonte, Minas Gerais, Brazil, operating under the supervision of the Secretaria de Estado de Saúde de Minas Gerais (SES-MG). The institution functions as one of Brazil's official public pharmaceutical laboratories and houses the Instituto Octávio Magalhães, which contains the Laborátório Central de Saúde Pública de Minas Gerais (Lacen-MG). Funed is organized into three operational pillars: an Industrial Park producing vaccines, antivenom sera, and essential medications; a Public Health Surveillance directorate delivering diagnostic, environmental, occupational, and pharmaceutical-quality laboratory services through the Lacen-MG network and seven macroregional laboratories; and a Research, Teaching, and Innovation directorate (DPD) operating as an Institute of Science and Technology with over 30 active research projects, 30+ deposited patents, and a Professional Master's in Biotechnology program.

The foundation's core technology stack combines pharmaceutical GMP manufacturing (RDC 658/2020, ISO 9001:2015) with specialized biological production, including Meningococcal C oligosaccharide-CRM197 conjugate vaccine manufacturing, hyperimmune equine plasma-based antivenom production on a 200-hectare experimental farm, and domestic API development for Entecavir. Funed operates the GAL national laboratory management system and integrates laboratory results with the Sinan notifiable disease surveillance system. The product portfolio includes the exclusive national supply of Meningococcal C vaccine (over 130 million cumulative doses since 2009, 12 million annually), the only domestic Thalidomide production (5 million tablets in 2021), the first Brazilian generic Entecavir 0.5mg for Hepatitis B, and a comprehensive antivenom sera range (antibothropic, anticrotalic, antielapidic, antiscorpionic, antitetanic, antirabic).

Funed operates a government-procurement revenue model with no commercial market exposure. All products are supplied exclusively to the Ministry of Health for the Sistema Único de Saúde (SUS) distribution, while laboratory services are provided to the state health network. The foundation is funded through intergovernmental transfers, Productive Development Partnerships (PDPs), and research grants from Fapemig and the Ministry of Health. End-user pricing is effectively zero, as services and medicines are delivered free of charge to citizens via SUS. Distribution is conducted solely through the Ministry of Health's central procurement system, SES-MG, and the public health laboratory network, with no private-sector, retail, or export channels.

Name

Funed - Fundação Ezequiel Dias

Legal name

Fundação Ezequiel Dias

Website

https://funed.mg.gov.br

Company type

Private

Founded year

1900

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Fundação Ezequiel Dias (Funed) is a Brazilian state foundation that produces vaccines, antivenom sera, and essential medicines exclusively for the Unified Health System (SUS). It is the sole national supplier of Meningococcal C vaccine and the only domestic producer of Thalidomide, and it operates the Central Public Health Laboratory of Minas Gerais (Lacen-MG).

Ownership category

akta.pro rank

Product category

Public Health Pharmaceuticals

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medicinal and Botanical Manufacturing (325411)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Public Health Financing, Budgeting & Grants Management (HLAJAMAC)

Keywords

• Pharmaceutical manufacturing
• Vaccine production
• Antivenom sera
• Public health laboratory
• Biological medicines

Headquarters

HQ city

Belo Horizonte, Minas Gerais

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Government Funding: Funed receives public funding from the State of Minas Gerais and Brazilian Ministry of Health for pharmaceutical production, laboratory services, and public health research. Revenue is derived from government contracts and transfers for product delivery to SUS.
2. Product Supply to SUS: Production and distribution of essential medications, vaccines, and sera to the Brazilian public health system. Products include Vacina Meningocócica C, Talidomida, Entecavir, and various antivenom sera, supplied exclusively through government procurement.
3. Laboratory Diagnostic Services: Central Public Health Laboratory (Lacen-MG) providing diagnostic testing services for disease surveillance, water quality, food safety, pharmaceutical monitoring, and occupational health across Minas Gerais.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Fundação Ezequiel Dias (Funed) is a state-owned Brazilian pharmaceutical laboratory that manufactures vaccines, antivenom sera, and essential medications, and operates the Central Public Health Laboratory of Minas Gerais (Lacen-MG). It supplies its products to the Brazilian Unified Health System (SUS) and the National Immunization Program (PNI), and runs research, teaching, and innovation programs through its Institute of Science and Technology.

Product overview

Funed is a public foundation that functions as a pharmaceutical laboratory and public health institute, organized into three main operational areas: Industrial Park (Parque Industrial) producing vaccines, antivenom sera, and medications; Public Health Surveillance (Vigilância em Saúde) including Lacen-MG laboratory services; and Research, Teaching, and Innovation (Pesquisa, Ensino e Inovação) through its Directorate of Research and Development (DPD). The Industrial Park is the sole national producer of Meningococcal C vaccine, the only domestic producer of Thalidomide, and produces a comprehensive portfolio of antivenom sera (pentavalent, crotalic, elapidic, scorpion, rabies, and tetanus) and Entecavir. The DPD operates as an ICT (Instituto de Ciência e Tecnologia) with over 30 active research projects and 30+ deposited patents, offering a Professional Master's in Biotechnology. Public health surveillance encompasses laboratory diagnostics, environmental monitoring, and pharmacovigilance services integrated with national information systems.

Differentiator

Problem solved

Functional benefit

Brands

• Instituto de Ciência e Tecnologia (ICT) Funed: Science and Technology Institute that encompasses the research and development directorate
• Instituto Octávio Magalhães (IOM)
• Laboratório Central de Saúde Pública de Minas Gerais (Lacen-MG)

Products and services

• Meningococcal C conjugate vaccine (MenC) Vaccine offered to the Brazilian Ministry of Health for use in the National Immunization Program (PNI), used for immunization against meningococcal C disease in pediatric and adolescent populations.
• Meningococcal ACWY conjugate vaccine (MenACWY) Vaccine offered to the Brazilian Ministry of Health for immunization against meningococcal disease caused by serogroups A, C, W, and Y, supplied to the public health system (SUS).
• Antivenom sera (soros antipeçonhentos) Hyperimmune antivenom sera produced for the treatment of envenomations from snakes, spiders, scorpions, and other venomous animals, supplied to the SUS for public health use.
• Thalidomide Thalidomide medication produced for the Brazilian public health system, used in the treatment of conditions such as severe dermatological and oncological diseases under the SUS.
• Entecavir Antiviral medication supplied to the SUS for the treatment of chronic hepatitis B.
• Lacen-MG public health laboratory services Centralized public health laboratory testing services provided to the Minas Gerais State Health Secretariat and the public health surveillance network, supporting disease diagnosis, epidemiological surveillance, and quality control.

Quantifiable outcome

• 100% of national Meningococcal C vaccine demand met by Funed
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Ministério da SaúdecoreStrategic or Co-development PartnerPrimary government partner for Productive Development Partnerships (PDP). Funed develops and produces medications under PDP agreements with the Ministry of Health, including Entecavir, Meningococcal C vaccine, and Talidomida for SUS distribution.
• BioManguinhos/Fiocruz (Rio de Janeiro)coreStrategic or Co-development PartnerPartnership for vaccine development and production. BioManguinhos serves as a technology partner in Productive Development Partnerships for pharmaceutical products.
• Farmanguinhos/FiocruzcoreStrategic or Co-development PartnerInstituto de Tecnologia em Fármacos (Farmanguinhos) partners with Funed for Entecavir production. Farmanguinhos handles manipulation, compression, and coating stages while Funed performs fractioning, filling, packaging, and quality control.
• Universidade Federal de Minas Gerais (UFMG)coreStrategic or Co-development PartnerAcademic partnership for research collaboration, graduate education, and scientific research projects in biotechnology and public health.
• GSK (GlaxoSmithKline)minorStrategic or Co-development PartnerTechnology transfer partner for product development, specifically related to Productive Development Partnerships for pharmaceutical products.
• Instituto ButantanminorStrategic or Co-development PartnerPartnership among official Brazilian pharmaceutical laboratories through Alfob (Associação dos Laboratórios Farmacêuticos Oficiais do Brasil) for knowledge sharing and collaborative development.
• Secretaria de Estado de Saúde de Minas Gerais (SES-MG)coreStrategic or Co-development PartnerFuned is part of the State Health System and operates integrated with SES-MG for epidemiological surveillance, laboratory services, and public health programs.
• Fapemig (Fundação de Amparo à Pesquisa do Estado de Minas)coreStrategic or Co-development PartnerResearch funding partner for scientific projects, providing grants and support for research and development activities at Funed.
• ANVISAcoreStrategic or Co-development PartnerRegulatory partnership for pharmaceutical registration, good manufacturing practice certification, and pharmacovigilance activities.
• CPqRR/Fiocruz Minas GeraisminorStrategic or Co-development PartnerResearch collaboration with Centro de Pesquisa Renné Rachou for scientific projects and knowledge sharing in health research.
• ICGEB (Itália)minorStrategic or Co-development PartnerInternational partnership with Centro de Engenharia Genética e Biotecnológica for research collaboration and technology exchange.
• Universidade Federal de Ouro Preto (UFOP)minorStrategic or Co-development PartnerAcademic partnership for research collaboration and scientific development in the biotechnology and pharmaceutical fields.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bio-Manguinhos / Fiocruz: Brazilian public pharmaceutical laboratory under Fiocruz, producing vaccines, diagnostics, and biotherapeutics for the SUS. Directly comparable as a fellow official laboratory and an active PDP partner of Funed, sharing the same public-health mandate and Brazil-exclusive distribution model.
• Haffkine Biopharmaceutical Corporation Ltd: Maharashtra state-owned pharmaceutical manufacturer producing vaccines, sera, and injectables for India's public health system. Comparable to Funed as a state-owned biologicals producer with antivenom and vaccine production serving a single dominant public-sector customer.
• Instituto Butantan: São Paulo state public institute producing vaccines (flu, HPV, dengue), antivenoms, and biopharmaceuticals for SUS. Closely comparable as an official Brazilian pharmaceutical laboratory with an analogous R&D + production + national-procurement model, partnered with Funed through Alfob.
• Farmanguinhos / Fiocruz: Fiocruz's official pharmaceutical laboratory producing generic and strategic medicines for SUS. Directly comparable as a public-sector drug manufacturer and a PDP partner collaborating with Funed on Entecavir production, distribution, and quality control.
• Laboratorios de Biológicos y Reactivos de México (Birmex): Mexican state-owned biological and pharmaceutical manufacturer producing vaccines, sera, and diagnostics for the Mexican public health system. Comparable to Funed as a government-owned biologics manufacturer serving national immunization and public health needs.
• Centro de Ingeniería Genética y Biotecnología (CIGB): Cuban state-owned biotech institute producing vaccines, therapeutics, and diagnostic systems for national health programs and export. Comparable to Funed in its integrated R&D-to-manufacturing model for vaccines and biologics under a public-health mandate.

Broad incumbents

• GSK (Vaccines Division): Global vaccine and pharmaceutical major with an active PDP technology-transfer partnership with Funed. Comparable as a producer of vaccines and biologics Funed also produces (e.g., conjugate vaccines), but operating at global scale as a multinational.
• Serum Institute of India: World's largest vaccine manufacturer by doses, producing vaccines and antisera for global public health programs. Comparable to Funed in the vaccine/sera manufacturing space, but operates globally and at vastly larger scale, with commercial export reach Funed lacks.

Regional players

• Instituto Nacional de Salud (Colombia): Colombian public health institute performing disease surveillance, diagnostics, and reference-laboratory services. Comparable to Funed's Lacen-MG role in epidemiological surveillance and laboratory network coordination, though focused on diagnostics rather than production.

Others

• Pan American Health Organization (PAHO): Regional WHO entity coordinating public health policy, immunization programs, and epidemiological surveillance across the Americas. Comparable as an institutional counterparty that channels funding and demand for vaccines and biologics Funed supplies to SUS.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/funda%C3%A7%C3%A3o-ezequiel-dias

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Funed - Fundação Ezequiel Dias